Condition: Relapsed/Refractory Multiple Myeloma · Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
This description comes directly from the study's public registry record.
Sanbin Wang, MD · 13187424131 · Sanbin1011@163.com
Sanbin Wang, MD
Always discuss trial participation with your own doctor first.
| Sanbin Wang | Kunming, Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06515262